Valuation: Novavax, Inc.

Market Cap 1.47B 1.26B 1.18B 1.08B 2.03B 141B 2.06B 13.96B 5.45B 70.88B 5.54B 5.42B 234B P/E 2026 *
-14.3x
P/E 2027 * -39.9x
Enterprise Value 1.69B 1.45B 1.36B 1.24B 2.33B 162B 2.36B 16.04B 6.25B 81.4B 6.36B 6.22B 269B EV / Sales 2026 *
4.54x
EV / Sales 2027 * 6.68x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day+6.18%
1 week+11.06%
Current month+22.13%
1 month+10.71%
3 months-0.45%
6 months-2.83%
Current year+33.04%
1 week 7.84
Extreme 7.835
9.2
1 month 7.15
Extreme 7.15
9.2
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
20/06/26 Fiscal year

Director

37,760 0.0230%
18/06/26 Free

Director

35,450 0.0216%
01/03/26 Fiscal year

Chief Financial Officer

275,198 0.1694%
Change 5-day change 1-year change 3-year change Capi.($)
+6.18%+11.06%+17.17%+10.78% 1.47B
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average +1.02%+5.10%+78.68%+115.21% 27.8B
Weighted average by Cap. +0.52%+4.75%+102.08%+147.75%

Financials

2026 *2027 *
Net sales 373M 319M 299M 274M 514M 35.68B 520M 3.53B 1.38B 17.93B 1.4B 1.37B 59.29B 266M 228M 213M 195M 366M 25.47B 371M 2.52B 983M 12.79B 999M 978M 42.32B
Net income -108M -92.12M -86.2M -78.9M -148M -10.29B -150M -1.02B -397M -5.17B -404M -395M -17.1B -37.93M -32.49M -30.4M -27.83M -52.22M -3.63B -52.91M -359M -140M -1.82B -142M -139M -6.03B
Net Debt 219M 188M 176M 161M 302M 20.95B 306M 2.07B 809M 10.53B 822M 804M 34.82B 303M 260M 243M 222M 417M 29.01B 423M 2.87B 1.12B 14.57B 1.14B 1.11B 48.2B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
21/08/26 $8.940 +6.18% 10,448,189
20/08/26 $8.420 -4.21% 5,976,486
19/08/26 $8.790 +10.84% 11,451,112
18/08/26 $7.930 -1.73% 2,015,486
17/08/26 $8.070 +0.25% 1,928,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.940USD
Average target price
14.00USD
Spread / Average Target
+56.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock